References
- Biocon Blog. Worldwide Prescription Drug & OTC Sales by Therapy Area in 2024. Biocon. Available at: http://www.patelsecurities.com/biocon-ltd/
- Reportlinker. APAC Biosimilar Market Forecast 2025. Biosimilar Development. 2018. Available at: https://www.biosimilardevelopment.com/doc/apac-biosimilar-market-forecast-0001
- Palmer, E. Novartis Adding $500M Biologics Plant in Singapore. Fierce Pharma. 2012. Available at: https://www.fiercepharma.com/supply-chain/novartis-adding-500m-biologics-plant-singapore
- CPhI. Surge Of Indian Biosimilars Market Forecast In 2019. Biosimilar Development. 2019. Available at: https://www.biosimilardevelopment.com/doc/surge-of-indian-biosimilars-market-forecast-in-0001
- Momin, Z.; Wijaya, C.; Bernardo, P. Biosimilars: Will Asia Go Big in Adoption and Manufacturing? Biosimilar Development. 2017. Available at: https://www.biosimilardevelopment.com/doc/will-asia-go-big-in-biosimilars-adoption-and-manufacturing-0001
- EP News Bureau. India an Emerging Hub for Biologics and Biosimilars: Report. Express Pharma. 2019. Available at: https://www.expresspharma.in/latest-updates/new-report-from-clarivate-analytics-highlights-india-as-an-emerging-hub-for-biologics-and-biosimilars/
- BS Reporter. Intas, Apotex to Develop Cancer Drug. Business Standard. 2013. Available at: https://www.business-standard.com/article/companies/intas-apotex-to-develop-cancer-drug-108050500041_1.html
- GaBI. India Releases Revised Guidelines for Similar Biologics. Generics and Biosimilars Initiative. 2016. Available at: http://www.gabionline.net/Guidelines/India-releases-revised-guidelines-for-similar-biologics
- Loeb, J. India’s New Biosimilar Guidelines and Their Relationship to the Rest of the World. Dechert LLP. 2012. Available at: https://www.jdsupra.com/post/contentViewerEmbed.aspx?fid=118b721d-4134-451c-8c19-4069ae4b856c.
- Jayakumar, P. B. India Emerges as a Hub for Biotech Drug Research, Says Report. Business Report. 2019. Available at: https://www.businesstoday.in/sectors/pharma/india-emerges-as-a-hub-for-biotech-drug-research-says-report/story/392218.html
- Meher, B. R.; Balan, S.; Mohanty, R. R.; Jena, M.; Das, S. Biosimilars in India; Current Status and Future Perspectives. J. Pharm. Bioallied Sci. 2019, 11, 12–15. DOI: 10.4103/jpbs.JPBS_167_18.
- Khoo, Y. S. K.; Tang, T. Y.; Goh, P. S.; Halimi, H. M.; Ab Ghani, A. An Update on the Registration of Biosimilars in Malaysia. Ther. Innov. Regul. Sci. 2017, 51, 55–59. DOI: 10.1177/2168479016664774.
- Abas, A. Regulatory Guidelines for Biosimilars in Malaysia. Biologicals 2011, 39, 339–342. DOI: 10.1016/j.biologicals.2011.06.009.
- Bas, T.; Oliu Castillo, C. Biosimilars in Developed and Developing East and Southeast Asian Countries: Japan, South Korea, and Malaysia—Overview, Evolution, and Regulations Assessment. Hindawi 2016, 1–12.
- Welch, A. The Thai FDA’s Approach to Biologics and Biosimilars. Biosimilar Development. 2017. Available at: https://www.biosimilardevelopment.com/doc/the-thai-fda-s-approach-to-biologics-and-biosimilars-0001.
- Homhuan, A.;Adcock, A. Biosimilars in Thailand. Tilleke & Gibbins. 2016. Available at: https://www.tilleke.com/resources/biosimilars-thailand.
- Thanaphollert, P.; Tungsanga, K. Towards Regulation of Similar Biotherapeutic Products: Thailand’s Perspective. Biologicals 2011, 39, 346–347. DOI: 10.1016/j.biologicals.2011.06.012.
- Srimalee, S. Siam Bioscience in Biopharma Push. The Nation Thailand. 2017. Available at: https://www.nationthailand.com/noname/30314370.
- Welch, A. Building Thailand’s Biosimilar Industry from the Ground up. Biosimilar Development. 2017. Available at: https://www.biosimilardevelopment.com/doc/building-thailand-s-biosimilar-industry-from-the-ground-up-0001.
- Wardiana, A.; Ningrum, R. A. The Emergence of Biosimilars in Indonesia: Guidelines, Challenges and Prospects. Annales Bogorienses 2016, 20, 37–46.
- Sparringa, R. Recent Trends in the Regulation of Biopharmaceuticals: Indonesian Perspectives. BADAN POM. 2015. Available at: https://cdn.ymaws.com/casss.site-ym.com/resource/resmgr/CMC_Japan_Speaker_Slides/2015_CMCJP_SparringaRoy.pdf.
- Dewi, L. K. M. Biosimilars Drugs. Cermin Dunia Kedokteran (CDK) 2018, 45, 9
- Maulia, E. Indonesia’s First Biomedicine Factory Opens. Nikkei Asian Review. 2018. Available at: https://asia.nikkei.com/Business/Pharmaceuticals/Indonesia-s-first-biomedicine-factory-opens2.
- GaBI. Singapore guidelines for biosimilars. Generics & Biosimilars Initiative. 2012. Available at: http://www.gabionline.net/Guidelines/Singapore-guidelines-for-biosimilars
- EDB Reporter. The Brave New World of Biosimilars. Singapore Economic Development Board. 2017. Available at: https://www.edb.gov.sg/en/about-edb/who-we-are.html.
- Poh, J.; Tam, K. T. Registration of Similar Biological products-Singapore’s Approach. Biologicals 2011, 39, 343–345. DOI: 10.1016/j.biologicals.2011.06.011.
- Health Sciences Authority. Guidance for Industry Post-Marketing Vigilance Requirements for Therapeutic Products. 2020. Available at: https://www.hsa.gov.sg/
- Soundarya Reddy, K.; et al. Regulatory Landscape of Biosimilars in Singapore: A Critical Overview. Elixir Bio Tech. 2012, 51A, 11084–11086.
- Tomas Gabriel, B. A. S.; Carolina, O. L. I. U. Biosimilars, Alternative Way for Expiration of Patents in the Biopharmaceutical Industry: Review of Many Countries in Relationship to Systematic Development, Regulations and Molecules Approved. International Journal of Pharmacy & Technology 2017, 9, 29549–29573.
- Han-Soo, L. Prestige Bio to develop biosimilars - Korea Biomedical Review. 2019. Available at: http://www.koreabiomed.com/news/articleView.html?idxno=6357.
- Center Biologic Policy Evaluation (CBPE). Taiwan Guideline on Biosimilar Products. Available at: https://biologicspolicy.com/country/taiwan.
- Chan, H. W.; Fang, C. H.; Lin, L.; Lin, H. C. . The Development of Biosimilars in Taiwan. Value in Health 2018, 21, S1–S115.
- Samantha DiGrande. Tanvex Submits BLA for Proposed Filgrastim Biosimilar. Center for Biosimilars. 2018. Available at: https://www.centerforbiosimilars.com/news/tanvex-submits-bla-for-proposed-filgrastim-biosimilar#:∼:text=Tanvex%20BioPharma%2C%20a%20Taiwan%2Dbased,proposed%20filgrastim%20biosimilar%20referencing%20Neupogen.
- GaBI. China releases draft biosimilars guidance. Generics & Biosimilars Initiative. 2014. Available at: http://www.gabionline.net/Guidelines/China-releases-draft-biosimilars-guidance.
- Wang, K. Biosimilars Are Regulated Differently in China. Pharma DJ 2015.
- Pategou, J. The China Biosimilars Market: Rise Of A Potential Powerhouse. Biosimilar Development. 2019. Available at: https://www.biosimilardevelopment.com/doc/the-china-biosimilars-market-rise-of-a-potential-powerhouse-0001.
- GaBI. Copy biologicals approved in China. Generics & Biosimilars Initiative. 2019. Available at: http://www.gabionline.net/Biosimilars/General/Copy-biologicals-approved-in-China
- The Center for Biosimilars Staff. China Approves Its First Biosimilar, Henlius’ Rituximab. The American Journal of Managed Care (AJMC). 2019. Available at: https://www.centerforbiosimilars.com/news/china-approves-its-first-biosimilar-henlius-rituximab.